DK3377516T3 - Sammensætning til behandling af cancer - Google Patents

Sammensætning til behandling af cancer Download PDF

Info

Publication number: DK3377516T3
Authority: DK; Denmark
Prior art keywords: cancer; treatment; composition
Prior art date: 2015-11-20

Application number

DK16867262.4T

Other languages

English (en)

Inventor

David A Scheinberg

Original Assignee

Memorial Sloan Kettering Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-20

Filing date

2016-11-18

Publication date

2022-09-19

2016-11-18 Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center

2022-09-19 Application granted granted Critical

2022-09-19 Publication of DK3377516T3 publication Critical patent/DK3377516T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001141—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Toxicology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Virology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK16867262.4T 2015-11-20 2016-11-18 Sammensætning til behandling af cancer DK3377516T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562258134P	2015-11-20	2015-11-20
PCT/US2016/062865 WO2017087857A1 (en)	2015-11-20	2016-11-18	Methods and compositions for treating cancer

Publications (1)

Publication Number	Publication Date
DK3377516T3 true DK3377516T3 (da)	2022-09-19

Family

ID=58717878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16867262.4T DK3377516T3 (da)	2015-11-20	2016-11-18	Sammensætning til behandling af cancer

Country Status (20)

Country	Link
US (1)	US11033613B2 (da)
EP (2)	EP3377516B1 (da)
JP (3)	JP6991969B2 (da)
KR (2)	KR102823333B1 (da)
CN (4)	CN116327902A (da)
AU (2)	AU2016356708B2 (da)
CA (1)	CA3005896C (da)
DK (1)	DK3377516T3 (da)
ES (1)	ES2926386T3 (da)
HR (1)	HRP20220994T1 (da)
HU (1)	HUE059694T2 (da)
LT (1)	LT3377516T (da)
MA (1)	MA43283B1 (da)
MD (1)	MD3377516T2 (da)
PL (1)	PL3377516T3 (da)
PT (1)	PT3377516T (da)
RS (1)	RS63561B1 (da)
SI (1)	SI3377516T1 (da)
SM (1)	SMT202200370T1 (da)
WO (1)	WO2017087857A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2010209T3 (pl) *	2006-04-10	2017-04-28	Sloan Kettering Inst For Cancer Res	Immunogeniczne peptydy WT-1 i sposoby ich użycia
US10441654B2 (en)	2014-01-24	2019-10-15	Children's Hospital Of Eastern Ontario Research Institute Inc.	SMC combination therapy for the treatment of cancer
EP3377516B1 (en)	2015-11-20	2022-06-15	Memorial Sloan Kettering Cancer Center	Composition for treating cancer
CA3019005A1 (en)	2016-05-18	2017-11-23	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017283480A1 (en)	2016-06-13	2019-01-24	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
SG10202105561PA (en)	2016-11-30	2021-07-29	Advaxis Inc	Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN117024560A (zh)	2016-12-22	2023-11-10	库尔生物制药有限公司	T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en)	2017-01-09	2023-12-26	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
CN111010875B (zh)	2017-03-15	2024-04-05	库尔生物制药有限公司	用于调节免疫应答的方法
WO2019006401A2 (en) *	2017-06-30	2019-01-03	Advaxis, Inc.	LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
KR20210032924A (ko)	2017-09-05	2021-03-25	토크 테라퓨틱스, 인코포레이티드	치료용 단백질 조성물 및 그의 제조 및 사용 방법
AU2018366131A1 (en) *	2017-11-08	2020-05-28	Advaxis, Inc.	Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
WO2019139896A1 (en)	2018-01-09	2019-07-18	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
US12018045B2 (en)	2018-03-06	2024-06-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	17-beta-hydroxywithanolides and use thereof in treating cancer
TWI851607B (zh) *	2018-10-05	2024-08-11	日商癌免疫研究所股份有限公司	良性腫瘤之預防或治療藥
TWI856047B (zh) *	2018-12-19	2024-09-21	美商信號生物製藥公司	多聚體ｔ細胞調節多肽及其使用方法
AU2020270975A1 (en) *	2019-04-10	2021-11-25	Memorial Sloan Kettering Cancer Center	Multi-valent immunotherapy composition and methods of use for treating WT1-positive cancers
WO2021096888A1 (en)	2019-11-12	2021-05-20	Foundation Medicine, Inc.	Methods of detecting a fusion gene encoding a neoantigen
WO2021138447A1 (en)	2019-12-31	2021-07-08	Elixirgen Therapeutics, Inc.	Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
CA3178156A1 (en) *	2020-04-07	2021-10-14	Metanoi Therapeutics, Inc.	Ethanolamine formulation for treating epithelial ovarian carcinoma
CA3169949A1 (en)	2020-05-12	2021-11-18	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en)	2020-09-09	2024-10-09	Cue Biopharma, Inc.	MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en)	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
JPH06505486A (ja)	1991-02-07	1994-06-23	モレキュメティクス，リミティド	βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
AU7518194A (en)	1993-07-29	1995-02-28	Regents Of The University Of California, The	Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
US5643786A (en)	1995-01-27	1997-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Method for isolating dendritic cells
US7030212B1 (en)	1998-07-31	2006-04-18	Haruo Sugiyama	Tumor antigen based on products of the tumor suppressor gene WT1
US7901693B2 (en)	1998-09-30	2011-03-08	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en)	1998-09-30	2008-02-12	Corixa Corporation	Compositions and method for WT1 specific immunotherapy
ATE399179T1 (de) *	1998-09-30	2008-07-15	Corixa Corp	Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
US7655249B2 (en)	1998-09-30	2010-02-02	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en)	1998-09-30	2006-10-03	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en)	1998-09-30	2006-06-20	Corixa Corporation	Composition and methods for WTI specific immunotherapy
US7144581B2 (en)	2000-10-09	2006-12-05	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
AU7859900A (en)	1999-10-04	2001-05-10	Corixa Corporation	Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en)	2000-02-22	2003-05-01	Alexander Gaiger	Compositions and methods for diagnosis and therapy of malignant mesothelioma
US7553494B2 (en)	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
DE60332355D1 (de)	2002-06-12	2010-06-10	Chugai Pharmaceutical Co Ltd	Hla-a24-restringiertes krebsantigenpeptid
KR101431312B1 (ko)	2003-06-27	2014-08-20	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	Ｗｔ1 백신 적응 환자의 선택 방법
SI2071028T1 (sl)	2003-11-05	2012-03-30	Int Inst Cancer Immunology Inc	Antigen peptid pridobljen iz WT ki veže HLA DR
US20060127409A1 (en)	2003-12-01	2006-06-15	Scheinberg David A	Bcr-abl vaccines and methods of use thereof
CA2548135C (en)	2003-12-01	2014-04-22	Sloan-Kettering Institute For Cancer Research	Synthetic hla binding peptide analogues and uses thereof
CA2626238C (en)	2005-10-17	2015-10-06	Sloan Kettering Institute For Cancer Research	Wt1 hla class ii-binding peptides and compositions and methods comprising same
DE102006014261A1 (de)	2006-03-28	2007-10-04	Dr.Ing.H.C. F. Porsche Ag	Luftleitvorrichtung für ein Fahrzeug
PL2010209T3 (pl)	2006-04-10	2017-04-28	Sloan Kettering Inst For Cancer Res	Immunogeniczne peptydy WT-1 i sposoby ich użycia
TWI455721B (zh)	2007-12-05	2014-10-11	癌免疫研究所股份有限公司	癌疫苗組合物
US20110136141A1 (en)	2009-12-03	2011-06-09	Abbott Laboratories	Peptide reagents and method for inhibiting autoantibody antigen binding
US20150104413A1 (en)	2012-01-13	2015-04-16	Memorial Sloan Kettering Cancer Center	Immunogenic wt-1 peptides and methods of use thereof
DK2945647T3 (da)	2013-01-15	2020-11-16	Memorial Sloan Kettering Cancer Center	Immunogene wt-1-peptider og anvendelsesmetoder deraf
CA2840988A1 (en) *	2013-02-05	2014-08-05	Nitto Denko Corporation	Wt1 peptide cancer vaccine composition for mucosal administration
KR20150130284A (ko) *	2013-03-15	2015-11-23	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	암 백신 및 이를 이용한 치료 방법
EA201690746A1 (ru)	2013-10-25	2016-12-30	Фармасайкликс Элэлси	Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
EP3065772B1 (en)	2013-11-05	2024-07-24	Cognate Bioservices, Inc.	Combinations of checkpoint inhibitors and therapeutics to treat cancer
KR20220062143A (ko) *	2014-01-06	2022-05-13	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
EP3119893A1 (en) *	2014-03-17	2017-01-25	Taplmmune Inc.	Nucleic acid molecule vaccine compositions and uses thereof
JP6515182B2 (ja) *	2015-05-20	2019-05-15	大日本住友製薬株式会社	Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
EP3377516B1 (en)	2015-11-20	2022-06-15	Memorial Sloan Kettering Cancer Center	Composition for treating cancer

2016
- 2016-11-18 EP EP16867262.4A patent/EP3377516B1/en active Active
- 2016-11-18 HR HRP20220994TT patent/HRP20220994T1/hr unknown
- 2016-11-18 JP JP2018526090A patent/JP6991969B2/ja active Active
- 2016-11-18 SI SI201631597T patent/SI3377516T1/sl unknown
- 2016-11-18 LT LTEPPCT/US2016/062865T patent/LT3377516T/lt unknown
- 2016-11-18 HU HUE16867262A patent/HUE059694T2/hu unknown
- 2016-11-18 PL PL16867262.4T patent/PL3377516T3/pl unknown
- 2016-11-18 CA CA3005896A patent/CA3005896C/en active Active
- 2016-11-18 DK DK16867262.4T patent/DK3377516T3/da active
- 2016-11-18 KR KR1020187017393A patent/KR102823333B1/ko active Active
- 2016-11-18 US US15/777,514 patent/US11033613B2/en active Active
- 2016-11-18 SM SM20220370T patent/SMT202200370T1/it unknown
- 2016-11-18 EP EP22175680.2A patent/EP4130026A1/en active Pending
- 2016-11-18 PT PT168672624T patent/PT3377516T/pt unknown
- 2016-11-18 CN CN202210862167.3A patent/CN116327902A/zh active Pending
- 2016-11-18 WO PCT/US2016/062865 patent/WO2017087857A1/en not_active Ceased
- 2016-11-18 AU AU2016356708A patent/AU2016356708B2/en active Active
- 2016-11-18 KR KR1020257020131A patent/KR20250099263A/ko active Pending
- 2016-11-18 MA MA43283A patent/MA43283B1/fr unknown
- 2016-11-18 ES ES16867262T patent/ES2926386T3/es active Active
- 2016-11-18 CN CN202210863749.3A patent/CN115920017A/zh active Pending
- 2016-11-18 CN CN201680077975.1A patent/CN108431022B/zh active Active
- 2016-11-18 RS RS20220828A patent/RS63561B1/sr unknown
- 2016-11-18 CN CN202210863762.9A patent/CN116327903A/zh active Pending
- 2016-11-18 MD MDE20180934T patent/MD3377516T2/ro unknown
2021
- 2021-12-08 JP JP2021198966A patent/JP2022033926A/ja active Pending
2022
- 2022-05-03 AU AU2022202973A patent/AU2022202973B2/en active Active
2023
- 2023-12-27 JP JP2023220529A patent/JP2024041809A/ja active Pending

Also Published As

Publication number	Publication date
LT3377516T (lt)	2022-09-26
AU2016356708A1 (en)	2018-07-05
MA43283A (fr)	2018-09-26
SI3377516T1 (sl)	2023-01-31
MA43283B1 (fr)	2022-08-31
CN116327902A (zh)	2023-06-27
US20180339030A1 (en)	2018-11-29
EP4130026A1 (en)	2023-02-08
MD3377516T2 (ro)	2022-10-31
HRP20220994T1 (hr)	2022-11-11
EP3377516B1 (en)	2022-06-15
WO2017087857A1 (en)	2017-05-26
SMT202200370T1 (it)	2022-11-18
AU2022202973A1 (en)	2022-05-26
US11033613B2 (en)	2021-06-15
CN108431022A (zh)	2018-08-21
JP2024041809A (ja)	2024-03-27
KR102823333B1 (ko)	2025-06-23
CN116327903A (zh)	2023-06-27
KR20180094922A (ko)	2018-08-24
JP2022033926A (ja)	2022-03-02
EP3377516A1 (en)	2018-09-26
PL3377516T3 (pl)	2022-10-10
KR20250099263A (ko)	2025-07-01
CA3005896A1 (en)	2017-05-26
CN115920017A (zh)	2023-04-07
PT3377516T (pt)	2022-09-23
CN108431022B (zh)	2022-08-09
JP2018538265A (ja)	2018-12-27
AU2022202973B2 (en)	2025-07-24
AU2016356708B2 (en)	2022-02-03
HUE059694T2 (hu)	2022-12-28
JP6991969B2 (ja)	2022-03-03
ES2926386T3 (es)	2022-10-25
RS63561B1 (sr)	2022-10-31
CA3005896C (en)	2025-09-23
EP3377516A4 (en)	2019-06-26

Publication	Publication Date	Title
DK3377516T3 (da)	2022-09-19	Sammensætning til behandling af cancer
DK3431105T3 (da)	2020-03-09	Medicinsk sammensætning til behandling af cancer
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
DK3166976T3 (da)	2022-04-11	Anti-pd-l1-kombinationer til behandling af tumorer
PL3283527T3 (pl)	2021-06-14	Leczenie skojarzone nowotworów
DK3326641T3 (da)	2019-09-30	Rna-holdig sammensætning til behandling af tumorsygdomme
DK3189082T3 (da)	2020-09-21	Anti-pd-l1-konjugater til behandling af tumorer
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK3851537T5 (da)	2024-08-19	Behandling af hyperbilirubinæmi
DK3119808T3 (da)	2019-10-28	Antistofsammensætninger til tumorbehandling
DK3261726T3 (da)	2019-06-24	Sammensætning til behandling af acne
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3148529T3 (da)	2021-12-13	Forbindelser til behandling af hjernecancer
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3186244T3 (da)	2020-07-13	Dioxolananaloger af uridin til behandling af cancer
DK3458052T3 (da)	2020-02-03	Kombinationsbehandling af cancer
DK3353177T3 (da)	2020-08-24	Tricykliske heterocykler til behandling af cancer
DK3213752T3 (da)	2019-09-02	Sammensætning til behandling af cancerstamceller
DK3164394T3 (da)	2020-05-04	Gls1-inhibitorer til behandling af sygdomme
DK3307267T3 (da)	2019-07-01	Behandling af multipel sklerose
DK3318115T3 (da)	2020-04-14	Maskine til behandling af svinegylle
DK3638293T3 (da)	2023-11-06	Sammensætninger til behandling af cancer
DK3468604T3 (da)	2021-04-19	Farmaceutiske kombinationer til behandling af cancer
DK3302573T3 (da)	2019-11-11	Sammensætning til behandlingen af hjernelæsioner
DK3478284T3 (da)	2023-12-04	Forbindelser og sammensætninger til behandling af cancer